Adrian Adams - Aralez Pharmaceuticals CEO, Director
CEO
Mr. Adrian Adams is Chief Executive Officer, Director of the Company. He is Chief Executive Officer since February 5, 2016. From May 2015 through February 5, 2016, Mr. Adams was the Chief Executive Officer and a director of Pozen, and served as a consultant to Pozen from April 2015 to May 2015. Previously, Mr. Adams served as Chief Executive Officer and President and as a director of Auxilium Pharmaceuticals Inc., a specialty biopharmaceutical company, from December 2011 until January 2015, when it was acquired by Endo International plc. Prior to joining Auxilium, from September 2011 to November 2011, Mr. Adams served as Chairman and Chief Executive Officer of Neurologix, Inc., a company focused on development of multiple innovative gene therapy development programs. Before Neurologix, Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc., a specialty pharmaceutical company, from February 2010 until May 2011 when it was acquired by Merck Co., Inc. Previously, Mr. Adams served as President and Chief Executive Officer of Sepracor Inc., a specialty pharmaceutical company, from March 2007 and May 2007, respectively, until February 2010 at which time Sepracor was acquired by Dainippon Sumitomo Pharma Co., Ltd. Prior to his appointment as Chief Executive Officer of Sepracor, Mr. Adams served as its Chief Operating Officer. Prior to joining Sepracor, Mr. Adams served as the President and Chief Executive Officer of Kos Pharmaceuticals, Inc., a specialty pharmaceutical company, from 2002 until its acquisition by Abbott Laboratories in December 2006. Mr. Adams has also held general management and senior international and national marketing positions at SmithKline Beecham, Novartis and ICI since 2016.
Age | 63 |
Tenure | 8 years |
Phone | 905-876-1118 |
Web | http://www.aralez.com |
Aralez Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (6.75) % which means that it has lost $6.75 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (262.08) %, meaning that it created substantial loss on money invested by shareholders. Aralez Pharmaceuticals' management efficiency ratios could be used to measure how well Aralez Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 274.57 M in liabilities. Aralez Pharmaceuticals has a current ratio of 0.78, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aralez Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Aralez Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aralez Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aralez to invest in growth at high rates of return. When we think about Aralez Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Found 5 records | CEO Age | ||
Michael Barrett | Magnite | 62 | |
Amy Armstrong | Interpublic Group of | N/A | |
Frank Slootman | ServiceNow | 57 | |
William McDermott | ServiceNow | 62 | |
John Donahoe | ServiceNow | 58 |
Management Performance
Return On Equity | -262.08 | |||
Return On Asset | -6.75 |
Aralez Pharmaceuticals Leadership Team
Elected by the shareholders, the Aralez Pharmaceuticals' board of directors comprises two types of representatives: Aralez Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aralez. The board's role is to monitor Aralez Pharmaceuticals' management team and ensure that shareholders' interests are well served. Aralez Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aralez Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Martin Thrasher, Independent Director | ||
Jason Aryeh, Independent Director | ||
Arthur Kirsch, Independent Chairman of the Board | ||
Jennifer Armstrong, Executive Vice President - Human Resources and Administration | ||
Neal Fowler, Independent Director | ||
James Tursi, Chief Medical Officer | ||
Seth Rudnick, Independent Director | ||
Scott Charles, CFO, Senior Vice President | ||
Mark Glickman, Chief Commercial Officer | ||
Robert Harris, Independent Director | ||
Eric Trachtenberg, Chief Compliance Officer, General Counsel, Corporate Secretary | ||
Kenneth Lee, Lead Independent Director | ||
Andrew Koven, President Chief Business Officer | ||
Adrian Adams, CEO, Director | ||
Michael Kaseta, Head of Finance and Interim CFO, Principal Financial Officer, Principal Accounting Officer |
Aralez Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aralez Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -262.08 | |||
Return On Asset | -6.75 | |||
Profit Margin | (99.50) % | |||
Operating Margin | (45.33) % | |||
Current Valuation | 233.57 M | |||
Shares Outstanding | 67.19 M | |||
Shares Owned By Insiders | 9.58 % | |||
Shares Owned By Institutions | 8.27 % | |||
Number Of Shares Shorted | 2.97 M | |||
Price To Earning | (0.85) X |
Pair Trading with Aralez Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aralez Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aralez Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Eli Lilly could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eli Lilly when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eli Lilly - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eli Lilly and to buy it.
The correlation of Eli Lilly is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eli Lilly moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eli Lilly moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eli Lilly can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Aralez Stock
If you are still planning to invest in Aralez Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aralez Pharmaceuticals' history and understand the potential risks before investing.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
CEOs Directory Screen CEOs from public companies around the world | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |